182 related articles for article (PubMed ID: 3315196)
1. How large should a phase II trial of a new drug be?
Simon R
Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
[TBL] [Abstract][Full Text] [Related]
2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
3. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
4. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic response in phase I trials of antineoplastic agents.
Estey E; Hoth D; Simon R; Marsoni S; Leyland-Jones B; Wittes R
Cancer Treat Rep; 1986 Sep; 70(9):1105-15. PubMed ID: 3527410
[TBL] [Abstract][Full Text] [Related]
6. Practical side of multistage clinical trials for screening new agents.
Herson J
Cancer Treat Rep; 1983 Jan; 67(1):71-5. PubMed ID: 6616494
[TBL] [Abstract][Full Text] [Related]
7. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
11. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
12. One- and two-stage designs for stratified phase II clinical trials.
London WB; Chang MN
Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
[TBL] [Abstract][Full Text] [Related]
13. Two-stage plans for patient accrual in phase II cancer clinical trials.
Lee YJ; Staquet M; Simon R; Catane R; Muggia F
Cancer Treat Rep; 1979; 63(11-12):1721-6. PubMed ID: 526910
[TBL] [Abstract][Full Text] [Related]
14. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
15. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
Ellenberg SS
Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
17. Predictive probability early termination plans for phase II clinical trials.
Herson J
Biometrics; 1979 Dec; 35(4):775-83. PubMed ID: 526523
[TBL] [Abstract][Full Text] [Related]
18. Phase II trials in cancer: present status and analysis methods.
Lee YJ
Drugs Exp Clin Res; 1986; 12(1-3):57-71. PubMed ID: 3732056
[TBL] [Abstract][Full Text] [Related]
19. New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
Deutsch E; Soria JC; Armand JP
Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990
[TBL] [Abstract][Full Text] [Related]
20. Phase II trials powered to detect tumor subtypes.
Roberts JD; Ramakrishnan V
Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
